William Blair Comments on Amgen Inc.’s FY2025 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at William Blair reduced their FY2025 EPS estimates for Amgen in a research note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings per share of $19.15 for the year, down from their previous estimate of $19.34. The consensus estimate for Amgen’s current full-year earnings is $19.45 per share.

Several other equities research analysts have also issued reports on the stock. StockNews.com lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Thursday, March 28th. Raymond James started coverage on Amgen in a report on Thursday, March 28th. They set a “market perform” rating on the stock. Daiwa Capital Markets raised Amgen from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $264.00 to $320.00 in a research note on Thursday, December 21st. Oppenheimer reissued an “outperform” rating and set a $350.00 target price on shares of Amgen in a research note on Thursday, February 1st. Finally, SVB Leerink cut Amgen from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $324.00 to $318.00 in a report on Wednesday, February 7th. Ten research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $296.95.

Amgen Trading Down 0.5 %

NASDAQ:AMGN opened at $262.75 on Friday. The company has a debt-to-equity ratio of 10.14, a current ratio of 1.65 and a quick ratio of 1.13. The business has a fifty day moving average price of $277.34 and a 200-day moving average price of $281.24. The firm has a market capitalization of $140.81 billion, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.46 and a beta of 0.58. Amgen has a one year low of $211.71 and a one year high of $329.72.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. Amgen had a return on equity of 154.27% and a net margin of 23.83%. The business had revenue of $8.20 billion during the quarter, compared to the consensus estimate of $8.13 billion. During the same period in the previous year, the company posted $4.09 EPS. The business’s quarterly revenue was up 19.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in AMGN. Vanguard Group Inc. grew its stake in Amgen by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 49,035,981 shares of the medical research company’s stock worth $13,178,910,000 after acquiring an additional 165,636 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Amgen by 12.9% in the fourth quarter. Morgan Stanley now owns 13,301,365 shares of the medical research company’s stock valued at $3,493,471,000 after purchasing an additional 1,523,665 shares during the period. Charles Schwab Investment Management Inc. grew its stake in Amgen by 1.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 8,819,690 shares of the medical research company’s stock worth $2,132,778,000 after purchasing an additional 94,565 shares in the last quarter. Moneta Group Investment Advisors LLC increased its holdings in Amgen by 83,875.6% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,541,011 shares of the medical research company’s stock worth $1,980,571,000 after purchasing an additional 7,532,031 shares during the period. Finally, Northern Trust Corp raised its position in Amgen by 3.8% during the 3rd quarter. Northern Trust Corp now owns 6,977,625 shares of the medical research company’s stock valued at $1,875,306,000 after purchasing an additional 255,463 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.43%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio is currently 72.06%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.